Recombinant Human Glycoprotein V/CD42d Protein, CF

Product Discontinued

Recombinant Human Glycoprotein V/CD42d Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When rhvWF-A2 (Catalog # 2764-WV) is coated at 1 μg/mL (100 μL/well), the concentration of rhGPV that produces 50% optimal binding response is found to be approximately 10-50 ng/mL. Measured by the ability of the immobilized protein to support the adhesion of thrombin-activated human platelets.

  When 5 x 10⁶ cells per well are added to rhGPV coated plates (5 μg/mL, 100 μL/well), approximately 50%-70% will adhere after 1 hour at 37 °C.

  Optimal dilutions should be determined by each laboratory for each application.

• Source: Mouse myeloma cell line, NS0-derived human Glycoprotein V/CD42d protein
  Gln17-Gly523, with a C-termninal 6-His tag
• Accession #: P40197
• N-terminal Sequence: No results obtained: Gln17 predicted
• Protein/Peptide Type: Recombinant Proteins
• Gene: GP5
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 56 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 75-85 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Glycoprotein V/CD42d Protein, CF

• platelet glycoprotein V
• CD42d
• glycoprotein V (platelet)
• Glycoprotein V
• GP5
• GPV

Background

GPV (platelet glycoprotein V; designated CD42d) is an 83 kDa type I transmembrane (TM) glycoprotein of the leucine-rich repeat (LRR) family (1, 2). It is expressed exclusively within the platelet / megakaryocyte lineage, where it noncovalently interacts with other platelet TM LRR proteins, GPIb alpha / beta and GPIX, at a ratio of one GPV to two of each other subunit (2). The GPI-V-IX complex tethers platelets to von Willebrand factor on the surface of injured endothelial cells. Absence of the complex results in Bernard-Soulier syndrome, a rare bleeding disorder (1 - 3). The human GPV cDNA encodes a 560 amino acid (aa) protein with a 16 aa signal sequence, a 507 aa extracellular domain (ECD) containing 15 LRR, a 21 aa TM sequence, and a short (16 aa) cytoplasmic tail that binds calmodulin in resting, but not activated platelets. The human GPV ECD shares 70%, 71% and 81% aa identity with mouse, rat and equine GPV, respectively. GPV can form soluble fragments of 80 kDa by ADAM10 or ADAM17 cleavage after P507, or 69 kDa by thrombin cleavage after R476 (1, 4, 5). High circulating soluble GPV may be an indicator of platelet activation, but may also be caused by high doses of aspirin (6 - 8). The function of GPV is not entirely clear. Deletion of GPV in mice does not produce any obvious change to surface expression or function of GPIb and GPIX, but surface expression of GPV requires GPIb (9, 10). Deletion studies also indicate that GPV may play a minor role in collagen adhesion, and may modify platelet aggregation in response to thrombin (3, 11 - 15).

1. Lanza, F. et al. (1993) J. Biol. Chem. 268:20801.
2. Hickey, M.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90:8327.
3. Ozaki, Y. et al. (2005) J. Thromb. Haemost. 3:1745.
4. Rabie, T. et al. (2005) J. Biol. Chem. 280:14462.
5. Gardiner, E.E. et al. (2007) J. Thromb. Haemost. 5:1530.
6. Wolff, V. et al. (2005) Stroke 36:e17.
7. Javela, K. et al. (2005) Transfusion 45:1504.
8. Aktas, B. et al. (2005) J. Biol. Chem. 280:39716.
9. Kahn, M.L. (1999) Blood 94:4112.
10. Strassel, C. et al. (2004) Eur. J. Biochem. 271:3671.
11. Nonne, C. et al. (2008) J. Thromb. Haemost. 6:210.
12. Moog, S. et al. (2001) Blood 98:1038.
13. Ramakrishnan, V. et al. (1999) Proc. Natl. Acad. Sci. USA 96:13336.
14. Ni, H. et al. (2001) Blood 98:368.
15. Andrews, R.K. et al. (2001) Blood 98:681.

Publications for Glycoprotein V/CD42d (4249-GP)(1)

Publication using 4249-GP

• R Vollenberg, R Jouni, PAA Norris, M Burg-Roder, N Cooper, MJ Rummel, G Bein, I Marini, B Bayat, R Burack, AH Lazarus, T Bakchoul, UJ Sachs Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia Haematologica, 2019-03-28;0(0):. 2019-03-28 [PMID: 30923095] (Human)

Bioinformatics

• Gene Symbol: GP5
• Uniprot:
  • P40197(Human)